Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision vs Conventional Infliximab Dosing in Pediatric Crohn's Disease
NCT05660746Phase 3Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jul 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of infliximab in Crohn's disease (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Rate of Deep Remission at 52 weeks. Started Jul 2023; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05660746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660746.